SUZ12 Recombinant Monoclonal Antibody

說明書

中文名稱：

SUZ12重組抗體
貨號(hào)：

CSB-RA159561A0HU
規(guī)格：

￥1320
圖片：
Western Blot
Positive WB detected in: Hela whole cell lysate, HepG2 whole cell lysate, MCF-7 whole cell lysate, HL60 whole cell lysate, THP-1 whole cell lysate, K562 whole cell lysate
All lanes: SUZ12 antibody at 1:2000
Secondary
Goat polyclonal to rabbit IgG at 1/50000 dilution
Predicted band size: 84 kDa
Observed band size: 90 kDa

IHC image of CSB-RA159561A0HU diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4℃ overnight. The primary is detected by a Goat anti-rabbit IgG polymer labeled by HRP and visualized using 0.05% DAB.

Immunoprecipitating SUZ12 in K562 whole cell lysate
Lane 1: Rabbit control IgG instead of CSB-RA159561A0HU in K562 whole cell lysate. For western blotting,a HRP-conjugated Protein G antibody was used as the secondary antibody (1/2000)
Lane 2: CSB-RA159561A0HU(2μg)+ K562 whole cell lysate(500μg)
Lane 3: K562 whole cell lysate (10μg)
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

產(chǎn)品描述：

CSB-RA159561A0HU SUZ12重組單克隆抗體是針對(duì)Polycomb抑制復(fù)合體2（PRC2）核心組分SUZ12開發(fā)的高特異性試劑，適用于多種分子生物學(xué)研究場(chǎng)景。該抗體識(shí)別的SUZ12蛋白作為表觀遺傳調(diào)控的關(guān)鍵介質(zhì)，通過介導(dǎo)組蛋白H3K27三甲基化參與干細(xì)胞分化、胚胎發(fā)育及腫瘤發(fā)生等生物學(xué)過程。經(jīng)嚴(yán)格驗(yàn)證，該抗體在Western Blot中可清晰檢測(cè)內(nèi)源性SUZ12蛋白表達(dá)，免疫組化實(shí)驗(yàn)?zāi)軠?zhǔn)確定位細(xì)胞核內(nèi)靶蛋白分布，免疫共沉淀實(shí)驗(yàn)成功捕獲PRC2復(fù)合體互作蛋白。推薦使用濃度范圍涵蓋WB（1:500-1:5000）、IHC（1:50-1:200）和IP（1:200-1:1000），同時(shí)支持ELISA檢測(cè)，為研究者提供靈活的實(shí)驗(yàn)方案選擇。該產(chǎn)品適用于腫瘤生物學(xué)研究、表觀遺傳修飾機(jī)制探索、基因沉默調(diào)控網(wǎng)絡(luò)解析等基礎(chǔ)科研領(lǐng)域，尤其適用于PRC2復(fù)合體功能研究、癌癥相關(guān)異常甲基化分析以及發(fā)育生物學(xué)模型構(gòu)建等前沿課題，為揭示SUZ12在疾病發(fā)生發(fā)展中的作用提供可靠工具。
Uniprot No.：

Q15022
基因名：

SUZ12
別名：

Polycomb protein SUZ12 (Chromatin precipitated E2F target 9 protein) (ChET 9 protein) (Joined to JAZF1 protein) (Suppressor of zeste 12 protein homolog), SUZ12, CHET9 JJAZ1 KIAA0160
反應(yīng)種屬：

Human
免疫原：

A synthesized peptide derived from human SUZ12
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
克隆類型：

Monoclonal
抗體亞型：

Rabbit IgG
純化方式：

Affinity-chromatography
克隆號(hào)：

1B10
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA, WB, IHC, IP

推薦稀釋比：

Application	Recommended Dilution
WB	1:500-1:5000
IHC	1:50-1:200
IP	1:200-1:1000

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
Immunoprecipitation (IP) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Polycomb group (PcG) protein. Component of the PRC2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-27' (H3K27me) of histone H3, leading to transcriptional repression of the affected target gene. The PRC2 complex may also serve as a recruiting platform for DNA methyltransferases, thereby linking two epigenetic repression systems. Genes repressed by the PRC2 complex include HOXC8, HOXA9, MYT1 and CDKN2A.
基因功能參考文獻(xiàn)：
1. Functional assays to reveal the targets of n-miR-G665 showed that polycomb protein Suz12 is regulated by n-miR-G665, which in turn regulates the expression of n-miR-G665 through feedback loop mechanism. PMID: 29379063
2. Data suggest the polycomb repressive complex 2 subunits EZH2, SUZ12, and EED protein axis as promising therapeutic target for treating sarcoma. PMID: 29415665
3. High SUZ12 expression is associated with invasion and metastasis of tumor budding cells in tongue squamous cell carcinoma. PMID: 27582550
4. we analyzed eight probands with clinically suspected Weaver syndrome by whole-exome sequencing and identified three mutations: a 25.4-kb deletion partially involving EZH2 and CUL1 ,a missense mutation , and a missense mutation in SUZ12 inherited from her father .In vitro functional analyses demonstrated that the identified EED and SUZ12 missense mutations cause decreased decreased trimethylation of lysine 27 of H3 PMID: 28229514
5. PRE-PIK3C2B interacts directly with YY1 in vitro and recruits PRC2 complex in vivo. The localization of PcG proteins including YY1 to PRE-PIK3C2B in HEK cells is decreased on knock-down of either YY1 or SUZ12. PMID: 23805300
6. EZH1, SUZ12 and UXT work synergistically to regulate pathway activation in the nucleus. PMID: 27127229
7. Mutation in the SUZ12 gene is associated with malignant peripheral nerve sheath tumors. PMID: 28124441
8. Overexpression of miR-105 inhibited cell proliferation, tumorigenesis, migration, invasion, and drug sensitivity, whereas overexpression of suppressor of Zeste 12 homolog antagonized the tumor-suppressive functions of miR-105. PMID: 28618952
9. Mutations of SUZ12 and EED are reported to have tumor suppressive functions. (Review) PMID: 27000413
10. The difference in the SUZ12 and CBX8 genes expression were significantly divergent between tumors and their marginal tissues. PMID: 26837964
11. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer PMID: 26268246
12. Data show that RAS protein activation was the initiating oncogenic event, with polycomb repressive complex 2 (PRC2) subunits impairment being a secondary event. PMID: 26457648
13. SUZ12 is a key molecule in the regulation of monoallelic expression of IGF2. PMID: 26407907
14. Overexpression of Suz12 was associated with lung adenocarcinoma. PMID: 25279705
15. found that expression of PcG proteins and H3K27me3 showed prognostic value in our study cohort PMID: 25243792
16. this study described that miR-489 expression level was significantly reduced in lung cancer samples (n = 115) and cell lines. Abnormal expression of miR-489 regulated the cells invasion by binding SUZ12 3'-UTR in vitro. PMID: 25833694
17. downregulation of SUZ12 and ZNF198 leads to epigenetic reprogramming of infected hepatocytes. Because both Plk1 and HOTAIR are elevated in many human cancers, we propose that their combined effects are involved in epigenetic reprogramming PMID: 25855382
18. Conclude that the expression of SUZ12 is increased along with the degree of infiltration and metastasis of gastric carcinoma. PMID: 26176059
19. Data show that overall enhancer of zeste 2 (EZH2), embryonic ectoderm development (EED) and suppressor of zeste 12 homolog (SUZ12) expression in the colorectal cancer (CRC) tissues was significantly increased than in the non-cancerous tissue. PMID: 25326896
20. Somatic mutations of SUZ12 have a central role in malignant transformation of peripheral nerve sheath tumors. PMID: 25305755
21. Polycomb repressive complex 2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. PMID: 25240281
22. reduction in the total SUZ12 level was not a sufficient cause of the resolution of the epigenetic bivalency of beta-cell transcription factors in embryonic stem cells. PMID: 24845830
23. malat1 promotes bladder cancer metastasis by associating with suz12. PMID: 24449823
24. Data shows EZH2 or SUZ12 depletion leads to HP1 loss from chromatin and degradation. PMID: 25047840
25. the polycomb group gene SUZ12 functions as tumour suppressor in peripheral nerve sheath tumors, high-grade gliomas and melanomas by cooperating with mutations in NF1 PMID: 25119042
26. provide evidences suggesting that SUZ12 is an oncogene in non-small cell lung cancer PMID: 24633887
27. postulate that this interparalog structural difference, together with low allelic recombination rates, could have caused a reduction in NAHGC between SUZ12 and SUZ12P during human evolution PMID: 24385046
28. SUZ12 depletion mediated by RNA interference (RNAi) led to a reduction of gastric cell numbers and arrested the cell cycle at G1/S point. PMID: 23735840
29. Polycomb Repressive Complex 2 overexpression is associated with small cell lung cancer. PMID: 23714854
30. SUZ12 inactivation results in apoptosis in human colon cancer stem cells. PMID: 23588203
31. SUZ12 promotes the proliferation of human EOC cells by inhibiting apoptosis and HRK is a novel SUZ12 target gene whose upregulation contributes to apoptosis induced by SUZ12 knockdown. PMID: 22964433
32. studies suggest a tumor suppressor role for PRC2 in human leukemia and suggest a hitherto unrecognized dynamic interplay between oncogenic NOTCH1 and PRC2 function PMID: 22237151
33. Genetic defects in PRC2 components other than EZH2 are not common in myeloid malignancies. PMID: 22308284
34. We propose Plk1 activity down-regulates ZNF198 and SUZ12, thereby enhancing both HBV replication and pX-mediated oncogenic transformation. PMID: 21480320
35. Results support the hypothesis that the abnormal expression of SUZ12 accounts for some of the unexplained features of mantle cell lymphoma, such as abnormal DNA repair and increased resistance to apoptosis. PMID: 20558579
36. histone modification including PRC2-mediated repressive histone marker H3K27me3 and active histone marker acH4 may involve in CD11b transcription during HL-60 leukemia cells reprogramming to terminal differentiation[polycomb repressive complex 2 ] PMID: 19578722
37. Loss of miR-200 during CSC formation increases Suz12 expression, Suz12 binding, H3-K27 trimethylation, and Polycomb-mediated repression of the E-cadherin gene. PMID: 20832727
38. SUZ12 blocks cell differentiation, as SUZ12 knockdown releases differentiation programs in a chronic myeloid blastic phase transformed cell line. PMID: 19847889
39. Endometrial stromal tumors(ESTs) are genetically heterogeneous, with prevalence of JAZF1-JJAZ1 fusion highest among ESTs of classic histology. Diagnostic utility of JAZF1-JJAZ1 fusion transcript assay in ESTs may be limited to classic histologic subset. PMID: 15043312
40. JJAZ1 gene recombination may have a role in mosaicism in neurofibromatosis type 1 PMID: 15257518
41. Data show that SUZ12 is distributed across large portions of over two hundred genes encoding key developmental regulators. PMID: 16630818
42. The JAZF1-JJAZ1 fusion is a frequent, although nonuniform, feature of endometrial stromal neoplasia. PMID: 17197920
43. SUZ12 regulates H3-K9 methylation in an EZH2-independent fashion. Knockdown of SUZ12 in human cells caused a reduction in H3K27me3 and H3K9me3, and altered the distribution of HP1 alpha. PMID: 17406994
44. The JAFZ1-JJAZ1 fusion gene is present in the endometrial stromal and smooth muscle components of endometrial stromal tumors. PMID: 17667554
45. SUZ12, a component of the polycomb repressor complex 2, is recruited to the beta-globin gene. PMID: 17970752
46. Both benign and malignant forms of endometrial stromal tumor have the JAZF1-JJAZ1 fusion, but only the malignant form also exhibits exclusion of the unrearranged JJAZ1 allele. PMID: 18077430
47. the two PRC2 components SUZ12 and EZH2 are sumoylated in vitro and in vivo PMID: 18628979
48. YY1 physically interacts with SUZ12 and can act as a mediator to recruit the polycomb group proteins and DNA methyltransferases to participate in the CEBPD gene silencing process PMID: 18753137
49. study shows normal endometrial stromal cells contain a specific chimeric RNA joining 5' exons of JAZF1 gene on chromosome 7p15 to 3' exons of JJAZ1/SUZ12 gene on chromosome 17q11; this RNA is translated into JAZF1-JJAZ1 with anti-apoptotic activity PMID: 18772439
50. The JAZF1-JJAZ1 gene fusion was not identified in any Uterine tumor resembling ovarian sex cord tumors PMID: 19542872
顯示更多

收起更多
相關(guān)疾病：

A chromosomal aberration involving SUZ12 may be a cause of endometrial stromal tumors. Translocation t(7;17)(p15;q21) with JAZF1. The translocation generates the JAZF1-SUZ12 oncogene consisting of the N-terminus part of JAZF1 and the C-terminus part of SUZ12. It is frequently found in all cases of endometrial stromal tumors, except in endometrial stromal sarcomas, where it is rarer.
亞細(xì)胞定位：

Nucleus.
蛋白家族：

VEFS (VRN2-EMF2-FIS2-SU(Z)12) family
組織特異性：

Overexpressed in breast and colon cancer.
數(shù)據(jù)庫鏈接：

HGNC: 17101

OMIM: 606245

KEGG: hsa:23512

STRING: 9606.ENSP00000316578

UniGene: Hs.462732

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XPNPEP1 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human